APA (7th ed.) Citation

Hsu, M., Chang, R., Wang, M., Chen, C., Chen, W., Lee, T., & Wang, C. (2025). Selective sodium-glucose cotransporter two inhibitor empagliflozin ameliorates diabetic cardiomyopathy by activating the AMPK/TFEB signaling pathway. Journal of Food & Drug Analysis, 33(4), 421. https://doi.org/10.38212/2224-6614.3563

Chicago Style (17th ed.) Citation

Hsu, Man-Chen, Ru-Wen Chang, Mu-Chun Wang, Chia-Hui Chen, Wen-Hua Chen, Tzong-Shyuan Lee, and Chih-Hsien Wang. "Selective Sodium-glucose Cotransporter Two Inhibitor Empagliflozin Ameliorates Diabetic Cardiomyopathy by Activating the AMPK/TFEB Signaling Pathway." Journal of Food & Drug Analysis 33, no. 4 (2025): 421. https://doi.org/10.38212/2224-6614.3563.

MLA (9th ed.) Citation

Hsu, Man-Chen, et al. "Selective Sodium-glucose Cotransporter Two Inhibitor Empagliflozin Ameliorates Diabetic Cardiomyopathy by Activating the AMPK/TFEB Signaling Pathway." Journal of Food & Drug Analysis, vol. 33, no. 4, 2025, p. 421, https://doi.org/10.38212/2224-6614.3563.